

**UNITED STATES OF AMERICA  
BEFORE THE FEDERAL TRADE COMMISSION**

<hr/>		
<b>In the Matter of</b>	)	
	)	
<b>PFIZER INC.,</b>	)	
<b>a corporation;</b>	)	
	)	
<b>UPJOHN INC.,</b>	)	
<b>a corporation;</b>	)	
	)	
<b>VIATRIS INC.</b>	)	<b>FTC File No. 191-1082</b>
<b>a corporation;</b>	)	
	)	
<b>MYLAN N.V.,</b>	)	
<b>a public limited liability company;</b>	)	
	)	
<b>and</b>	)	
	)	
<b>UTAH ACQUISITION SUB INC.,</b>	)	
<b>a corporation.</b>	)	
<hr/>	)	

**AGREEMENT CONTAINING CONSENT ORDERS**

The Federal Trade Commission (“Commission”) has initiated an investigation of Proposed Respondent Pfizer Inc.’s (“Pfizer”) proposal to spin off its Upjohn division and combine it with the assets of Proposed Respondent Mylan N.V. Upon consummation, the combination is expected to be renamed Viatrix Inc. and will be comprised of certain legacy Pfizer assets held by Proposed Respondent Upjohn Inc. and its subsidiaries, Proposed Respondent Pfizer’s Greenstone LLC business, and all of the assets of Proposed Respondent Mylan N.V., collectively “Proposed Respondents.” The Commission’s Bureau of Competition has prepared a draft administrative complaint (“Draft Complaint”).

The Bureau of Competition and Proposed Respondents enter into this Agreement Containing Consent Orders (“Consent Agreement”) to divest certain assets and to provide other relief to resolve the allegations in the Draft Complaint through a proposed Decision and Order and Order to Maintain Assets, all of which are attached, to present to the Commission.

**IT IS HEREBY AGREED** by and between Proposed Respondents, by their duly authorized officers and attorneys, and counsel for the Commission that:

1. Proposed Respondent Pfizer Inc. is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and

*Pfizer Inc., et al.*

FTC File No. 191-1082

- principal place of business located at 235 East 42<sup>nd</sup> Street, New York, New York 10017.
2. Proposed Respondent Upjohn Inc. is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and principal place of business located at 235 East 42<sup>nd</sup> Street, New York, New York 10017. Upjohn Inc. is expected to be renamed Viatrix Inc. and will become Respondent Viatrix under the Orders, with its executive offices and principal place of business located at 1000 Mylan Boulevard, Canonsburg, Pennsylvania 15317.
  3. Proposed Respondent Mylan N.V. is a public limited liability company organized, existing, and doing business under and by virtue of the laws of the Kingdom of the Netherlands with its executive offices and principal place of business located at Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, England. Mylan N.V.'s United States address for service of process in this matter is as follows: 1000 Mylan Boulevard, Canonsburg, Pennsylvania 15317.
  4. Proposed Respondent Utah Acquisition Sub Inc. is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and principal place of business located at 235 East 42<sup>nd</sup> Street, New York, New York 10017. Upon completion of the combination, Utah Acquisition Sub Inc. will become a subsidiary of Respondent Viatrix Inc. with its executive offices and principal place of business located at 1000 Mylan Boulevard, Canonsburg, Pennsylvania 15317.
  5. Proposed Respondents admit all the jurisdictional facts set forth in the Draft Complaint.
  6. Proposed Respondents waive:
    - a. any further procedural steps;
    - b. the requirement that the Decision and Order and the Order to Maintain Assets contain a statement of findings of fact and conclusions of law;
    - c. all rights to seek judicial review or otherwise to challenge or contest the validity of the Decision and Order or the Order to Maintain Assets entered pursuant to this Consent Agreement; and
    - d. any claim under the Equal Access to Justice Act.
  7. This Consent Agreement is for settlement purposes only and does not constitute an admission by the Proposed Respondents that the law has been violated as alleged in the Draft Complaint, or that the facts as alleged in the Draft Complaint, other than jurisdictional facts, are true.
  8. Proposed Respondents shall submit an initial compliance report, pursuant to Commission Rule 2.33, 16 C.F.R. § 2.33, no later than 30 days after the date on which Proposed Respondents execute this Consent Agreement, and subsequent compliance reports every

*Pfizer Inc., et al.*

FTC File No. 191-1082

30 days thereafter until the Order to Maintain Assets becomes final. After the Order to Maintain Assets becomes final, the reporting obligations contained in the Order to Maintain Assets shall control and the reporting obligations under this Consent Agreement (other than the requirement to submit an initial report) shall cease. Each compliance report shall set forth in detail the manner in which Proposed Respondents have complied, have prepared to comply, are complying, and will comply with the Consent Agreement, Decision and Order, and the Order to Maintain Assets. Proposed Respondents shall provide sufficient information and documentation to enable the Commission to determine independently whether Proposed Respondents are in compliance with the Consent Agreement, the Decision and Order, and the Order to Maintain Assets.

9. Each compliance report submitted pursuant to Paragraph 8 above shall be verified in the manner set forth in 28 U.S.C. § 1746 by the Chief Executive Officer or other officer or employee specifically authorized to perform this function. Commission Rule 2.41(a), 16 C.F.R. §2.41(a), requires that the Commission receive an original and one copy of each compliance report. Proposed Respondents shall electronically file an original of each compliance report with the Secretary of the Commission at [ElectronicFilings@ftc.gov](mailto:ElectronicFilings@ftc.gov) and an electronic copy of the report with the Compliance Division at [bccompliance@ftc.gov](mailto:bccompliance@ftc.gov). In addition, Proposed Respondents shall provide a copy of each compliance report to the Monitor, if one has been appointed pursuant to the Decision and Order or the Order to Maintain Assets.
10. This Consent Agreement, and any compliance reports filed pursuant to this Consent Agreement, shall not become part of the public record of the proceeding unless and until the Commission accepts the Consent Agreement. If the Commission accepts this Consent Agreement, the Commission will place it, together with the Complaint, the proposed Decision and Order, the Order to Maintain Assets, an explanation of the provisions of the proposed Decision and Order and the Order to Maintain Assets, and any other information that may help interested persons understand the orders, on the public record for the receipt of comments for 30 days.
11. Because there may be interim competitive harm, the Commission may issue and serve its Complaint (in such form as the circumstances may require) and the Order to Maintain Assets in this matter at any time after it accepts the Consent Agreement for public comment.
12. This Consent Agreement contemplates that, if the Commission accepts the Consent Agreement, the Commission thereafter may withdraw its acceptance of this Consent Agreement and notify Proposed Respondents, in which event the Commission will take such action as it may consider appropriate. If the Commission does not subsequently withdraw such acceptance pursuant to Commission Rule 2.34, 16 C.F.R. § 2.34, and it has already issued the Complaint and the Order to Maintain Assets, the Commission may, without further notice to Proposed Respondents, issue the attached Decision and Order containing an order to divest and providing for other relief in disposition of the proceeding.

*Pfizer Inc., et al.*

FTC File No. 191-1082

13. The Decision and Order and the Order to Maintain Assets shall become final upon service. Delivery of the Complaint, the Decision and Order, and the Order to Maintain Assets to Proposed Respondents by any means provided in Commission Rule 4.4(a), 16 C.F.R. § 4.4(a), or by delivery to United States counsel for Proposed Respondents identified in this Consent Agreement, shall constitute service to Proposed Respondents. Proposed Respondents waive any rights they may have to any other manner of service. Proposed Respondents also waive any rights they may otherwise have to service of any Appendices attached to or incorporated by reference into the Decision and Order or the Order to Maintain Assets, if Proposed Respondents are already in possession of such Appendices, and agree that they are bound to comply with and will comply with the Decision and Order and the Order to Maintain Assets to the same extent as if they had been served with copies of the Appendices.
14. The Complaint may be used in construing the terms of the Decision and Order and the Order to Maintain Assets, and no agreement, understanding, representation, or interpretation not contained in the Decision and Order, the Order to Maintain Assets, or the Consent Agreement may be used to vary or contradict the terms of the Decision and Order or the Order to Maintain Assets.
15. By signing this Consent Agreement, Proposed Respondents represent and warrant that:
  - a. they can fulfill all the terms of and accomplish the full relief contemplated by the Decision and Order and the Order to Maintain Assets, including, among other things, effectuating all required divestitures, assignments, and transfers, and obtaining any necessary approvals from governmental authorities, leaseholders, and other third parties to effectuate the divestitures, assignments, and transfers; and
  - b. all parents, subsidiaries, affiliates, and successors necessary to effectuate the full relief contemplated by this Consent Agreement, the Decision and Order, and the Order to Maintain Assets are parties to this Consent Agreement and are bound as if they had signed this Consent Agreement and were made parties to this proceeding, or are within the control of parties to this Consent Agreement, the Decision and Order, and the Order to Maintain Assets, or will be after the acquisition.
16. Proposed Respondents have read the Draft Complaint, the proposed Decision and Order, and the Order to Maintain Assets. Proposed Respondents agree to comply with the terms of the proposed Decision and Order and the Order to Maintain Assets from the date they sign this Consent Agreement. Proposed Respondents understand that once the Commission has issued the Decision and Order and the Order to Maintain Assets, they will be required to file one or more compliance reports setting forth in detail the manner in which they have complied, have prepared to comply, are complying, and will comply with the Decision and Order and the Order to Maintain Assets. When final, the Decision and Order and the Order to Maintain Assets shall have the same force and effect and may be altered, modified, or set aside in the same manner and within the same time as

*Pfizer Inc., et al.*

FTC File No. 191-1082

provided by statute for other orders. Proposed Respondents further understand that they may be liable for civil penalties in the amount provided by law for each violation of the Decision and Order and of the Order to Maintain Assets.

*Pfizer Inc., et al.*

FTC File No. 191-1082

**PFIZER INC.**

By: \_\_\_\_\_

Albert Bourla, DVM, Ph.d  
Chairman and Chief Executive Officer  
Pfizer Inc.

Date: \_\_\_\_\_

By: \_\_\_\_\_

Harry T. Robins, Esq.  
Scott A. Stempel, Esq.  
Morgan, Lewis & Bockius LLP  
Counsel for Pfizer Inc.

Date: \_\_\_\_\_

*Pfizer Inc., et al.*

FTC File No. 191-1082

**UPJOHN INC.**

**VIATRIS INC.**

**UTAH ACQUISITION SUB INC.**

By: \_\_\_\_\_

Michael Goettler

President

Upjohn Inc. (and on behalf of Viatris Inc.)

Date: \_\_\_\_\_

By: \_\_\_\_\_

Michael Goettler

President

Utah Acquisition Sub Inc.

By: \_\_\_\_\_

Harry T. Robins, Esq.

Scott A. Stempel, Esq.

Morgan, Lewis & Bockius LLP

Counsel for Upjohn Inc., Viatris Inc., and Utah Acquisition Sub Inc.

Date: \_\_\_\_\_

*Pfizer Inc., et al.*

FTC File No. 191-1082

**MYLAN N.V.**

By: \_\_\_\_\_

Heather Bresch  
Chief Executive Officer  
Mylan N.V.

Date: \_\_\_\_\_

By: \_\_\_\_\_

Yonatan Even, Esq.  
Margaret Segall D'Amico, Esq.  
Cravath, Swaine & Moore LLP  
Counsel for Mylan N.V.

Date: \_\_\_\_\_



*Pfizer Inc., et al.*

FTC File No. 191-1082

**FEDERAL TRADE COMMISSION**

By: \_\_\_\_\_

Jasmine Y. Rosner  
Attorney  
Bureau of Competition

\_\_\_\_\_  
Lynda Lao  
Acting Deputy Assistant Director  
Bureau of Competition

\_\_\_\_\_  
Daniel K. Zach  
Acting Assistant Director  
Bureau of Competition

\_\_\_\_\_  
Daniel Francis  
Deputy Director  
Bureau of Competition

\_\_\_\_\_  
Ian R. Conner  
Director  
Bureau of Competition

Date: \_\_\_\_\_